Myeloma

Fast Facts:

  • Most common primary bone malignancy in adults.  
  • Lifetime risk is 1:143
  • 5-year survival: 45%

Indications for PET/CT

PET/CT has become a valuable diagnostic and management tool for myeloma patients (including solitary and multiple myeloma, non-secretory myeloma, relapsing disease, and extramedullary myeloma). It has been used successfully in many aspects of the disease process, including:

  • Diagnosis
  • Initial Staging
  • Assessing Response to Therapy & Prognosis
  • Recurrence, Restaging & Management

PET/CT Presentations/Manifestations:

  • Most commonly, active myeloma presents with multiple, well-defined FDG-avid lytic lesions (typically involving the axial and proximal appendicular skeleton). 
  • Myeloma can present with diffuse skeletal increased FDG-uptake without well-defined lesions on the CT portion of the exam (the bones may appear osteopenic, without evidence of cortical destruction).
  • If multiple foci of FDG uptake are noted without associated CT abnormalities, this likely represents early active disease (it is estimated that 30-50% of bone loss is required before lesions become visible on radiographs).
  • Scattered non-avid lytic lesions are presumed to represent treated lesions.
  • Extramedullary lesions most frequently involve the liver, spleen, lymph nodes and subcutaneous soft tissues.